Teva Chief Seeks Growth Beyond $40.5 Billion Allergan DealBy
Israeli company may target specialty assets next, CEO says
Enlarged business has 338 treatments awaiting FDA approval
Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generics unit, which closed Tuesday, doesn’t signal that the Israeli drugmaker will let up its quest for innovative branded medicines.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.